Pazopanib versus sunitinib for the treatment of metastatic renal cell carcinoma patients with poor-risk features
Crossref DOI link: https://doi.org/10.1007/s00280-016-3093-8
Published Online: 2016-06-21
Published Print: 2016-08
Update policy: https://doi.org/10.1007/springer_crossmark_policy
Kim, Jwa Hoon
Park, Inkeun
Lee, Jae Lyun
Funding for this research was provided by:
Korean Ministry of Health and Welfare (HI12C1788, HI14C1931, HI14C1731)
License valid from 2016-06-21